XERIS PHARMACEUTICALS Trademark

Trademark Overview

On Wednesday, May 17, 2017, a trademark application was filed for XERIS PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the XERIS PHARMACEUTICALS trademark a serial number of 87452737. The federal status of this trademark filing is REGISTERED as of Tuesday, December 26, 2017. This trademark is owned by Xeris Pharmaceuticals, Inc.. The XERIS PHARMACEUTICALS trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

providing information in the field of pharmaceuticals and medicines; providing information relating to diabetes, epilepsy, hyperinsulinism, and autoimmune diseases
xeris pharmaceuticals

General Information

Serial Number87452737
Word MarkXERIS PHARMACEUTICALS
Filing DateWednesday, May 17, 2017
Status700 - REGISTERED
Status DateTuesday, December 26, 2017
Registration Number5364202
Registration DateTuesday, December 26, 2017
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 10, 2017

Trademark Statements

Goods and Servicesproviding information in the field of pharmaceuticals and medicines; providing information relating to diabetes, epilepsy, hyperinsulinism, and autoimmune diseases
NOT AVAILABLE"PHARMACEUTICALS"

Classification Information

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, May 22, 2017
Primary Code044
First Use Anywhere DateWednesday, November 30, 2011
First Use In Commerce DateWednesday, November 30, 2011

Trademark Owner History

Party NameXeris Pharmaceuticals, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressChicago, IL 60601
Party NameXeris Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressAustin, TX 78705
Party NameXeris Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAustin, TX 78705

Trademark Events

Event DateEvent Description
Monday, May 22, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, May 20, 2017NEW APPLICATION ENTERED
Tuesday, October 10, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, August 14, 2017ASSIGNED TO EXAMINER
Monday, August 14, 2017EXAMINERS AMENDMENT E-MAILED
Monday, August 14, 2017NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, August 14, 2017EXAMINERS AMENDMENT -WRITTEN
Monday, August 14, 2017ASSIGNED TO LIE
Monday, August 14, 2017EXAMINER'S AMENDMENT ENTERED
Tuesday, September 5, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 20, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 10, 2017PUBLISHED FOR OPPOSITION
Tuesday, December 26, 2017REGISTERED-PRINCIPAL REGISTER
Wednesday, June 27, 2018TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, June 27, 2018APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, May 22, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, May 22, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, May 22, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, May 22, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, May 22, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, June 23, 2022ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Monday, December 26, 2022COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Wednesday, September 4, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, September 4, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, July 3, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, May 19, 2022ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, December 20, 2023TEAS SECTION 7 REQUEST RECEIVED
Wednesday, December 20, 2023TEAS SECTION 8 & 15 RECEIVED

Related Keywords

pharmaceuticals xeris providing information hyperinsulinism diseases epilepsy autoimmune relating field medicines